27756035|t|Detection of circulating tumour cells may add value in endometrial cancer management
27756035|a|To evaluate the role of circulating tumour cells (CTCs) in patients with endometrial cancer (EC). This study included 40 patients with a pre-operative diagnosis of high-risk EC between April 2015 and May 2016. Patients were further divided into high-risk (grade 3, non-endometrioid, myometrial invasion ≥1/2 and stage III-IV) and high-intermediate-risk (grade 2-3, endometrioid, myometrial invasion <1/2 and stage I-II) groups according to postoperative pathological results. CTCs were detected using the CellSearch system, and CTC results were correlated with standard clinicopathological characteristics and serum tumour marker CA125 / HE4 status using Chi-squared test, continuity correction or Fisher's exact test. The pharmacodynamic effect was detected after the first cycle of adjuvant therapy. Patients were followed up for 13 months to assess outcomes. Fifteen percent of patients had one or more CTCs. The presence of CTCs was found to be significantly associated with cervical involvement (83.33% vs 11.76%, p=0.00). No significant difference in CTC - positive rates was detected between the high-risk and high-intermediate-risk groups, and no significant correlation was found between CTCs and serum CA125 / HE4, either by positive rates or exact serum levels of the conventional tumour markers. No more CTCs were detected after the first cycle of standard chemotherapy in this study, and no distant metastases or recurrence were found in the CTC - positive patients during the follow-up period. The presence of CTC s was correlated with cervical involvement. Early-stage EC patients with CTCs may benefit from additional adjuvant therapies. Assessment of CTCs may be useful in the management of high-risk EC patients.
27756035	0	9	Detection	T061	C1511790
27756035	13	37	circulating tumour cells	T025	C0027625
27756035	55	73	endometrial cancer	T191	C0476089
27756035	74	84	management	T058	C0376636
27756035	88	96	evaluate	T058	C0220825
27756035	109	133	circulating tumour cells	T025	C0027625
27756035	135	139	CTCs	T025	C0027625
27756035	144	152	patients	T101	C0030705
27756035	158	176	endometrial cancer	T191	C0476089
27756035	178	180	EC	T191	C0476089
27756035	188	193	study	T062	C2603343
27756035	206	214	patients	T101	C0030705
27756035	222	235	pre-operative	T079	C0445204
27756035	249	258	high-risk	T033	C0332167
27756035	259	261	EC	T191	C0476089
27756035	270	280	April 2015	T079	C3715024
27756035	285	293	May 2016	T079	C3812381
27756035	295	303	Patients	T101	C0030705
27756035	330	339	high-risk	T033	C0332167
27756035	341	392	grade 3, non-endometrioid, myometrial invasion ≥1/2	T201	C1300661
27756035	397	409	stage III-IV	T201	C1300072
27756035	415	437	high-intermediate-risk	T033	C3640764
27756035	438	488	(grade 2-3, endometrioid, myometrial invasion <1/2	T201	C1300661
27756035	493	503	stage I-II	T201	C1300072
27756035	505	511	groups	T078	C0441833
27756035	525	538	postoperative	T079	C0032790
27756035	539	551	pathological	T169	C1521733
27756035	552	559	results	T169	C1274040
27756035	561	565	CTCs	T025	C0027625
27756035	571	579	detected	T061	C1511790
27756035	590	607	CellSearch system	T060	C0430022
27756035	613	616	CTC	T025	C0027625
27756035	617	624	results	T169	C1274040
27756035	630	640	correlated	T080	C1707520
27756035	646	654	standard	T080	C1442989
27756035	655	674	clinicopathological	T169	C1521733
27756035	675	690	characteristics	T080	C1521970
27756035	695	733	serum tumour marker CA125 / HE4 status	T033	C0730483
27756035	715	720	CA125	T109,T129	C0006610
27756035	723	726	HE4	T116	C2707001
27756035	740	756	Chi-squared test	T060	C0430022
27756035	783	802	Fisher's exact test	T170	C1708064
27756035	808	830	pharmacodynamic effect	T044	C1868979
27756035	835	843	detected	T061	C1511790
27756035	854	865	first cycle	T079	C1511572
27756035	869	885	adjuvant therapy	T061	C0677850
27756035	887	895	Patients	T101	C0030705
27756035	920	926	months	T079	C0439231
27756035	930	945	assess outcomes	T057	C0085565
27756035	955	962	percent	T081	C0439165
27756035	966	974	patients	T101	C0030705
27756035	991	995	CTCs	T025	C0027625
27756035	1013	1017	CTCs	T025	C0027625
27756035	1034	1047	significantly	T078	C0750502
27756035	1048	1063	associated with	T080	C0332281
27756035	1064	1072	cervical	T082	C0205064
27756035	1073	1084	involvement	T169	C1314939
27756035	1116	1127	significant	T078	C0750502
27756035	1128	1138	difference	T080	C1705242
27756035	1142	1145	CTC	T025	C0027625
27756035	1148	1156	positive	T033	C1446409
27756035	1157	1162	rates	T081	C1521828
27756035	1167	1175	detected	T061	C1511790
27756035	1188	1197	high-risk	T033	C0332167
27756035	1202	1231	high-intermediate-risk groups	T033	C3640764
27756035	1240	1251	significant	T078	C0750502
27756035	1252	1263	correlation	T080	C1707520
27756035	1282	1286	CTCs	T025	C0027625
27756035	1291	1296	serum	T031	C0229671
27756035	1297	1302	CA125	T109,T129	C0006610
27756035	1305	1308	HE4	T116	C2707001
27756035	1320	1328	positive	T033	C1446409
27756035	1329	1334	rates	T081	C1521828
27756035	1344	1349	serum	T031	C0229671
27756035	1350	1356	levels	T080	C0441889
27756035	1364	1391	conventional tumour markers	T123	C0041366
27756035	1401	1405	CTCs	T025	C0027625
27756035	1411	1419	detected	T061	C1511790
27756035	1430	1441	first cycle	T079	C1511572
27756035	1445	1453	standard	T080	C1442989
27756035	1454	1466	chemotherapy	T061	C3665472
27756035	1475	1480	study	T062	C2603343
27756035	1489	1521	distant metastases or recurrence	T033	C0243095
27756035	1540	1543	CTC	T025	C0027625
27756035	1546	1554	positive	T033	C1446409
27756035	1555	1563	patients	T101	C0030705
27756035	1575	1584	follow-up	T058	C1522577
27756035	1585	1591	period	T079	C1948053
27756035	1609	1612	CTC	T025	C0027625
27756035	1609	1614	CTC s	T025	C0027625
27756035	1619	1629	correlated	T080	C1707520
27756035	1635	1643	cervical	T082	C0205064
27756035	1644	1655	involvement	T169	C1314939
27756035	1657	1668	Early-stage	T079	C2363430
27756035	1669	1671	EC	T191	C0476089
27756035	1672	1680	patients	T101	C0030705
27756035	1686	1690	CTCs	T025	C0027625
27756035	1695	1702	benefit	T081	C0814225
27756035	1708	1718	additional	T169	C1524062
27756035	1719	1737	adjuvant therapies	T061	C0677850
27756035	1739	1749	Assessment	T058	C0220825
27756035	1753	1757	CTCs	T025	C0027625
27756035	1779	1789	management	T058	C0376636
27756035	1793	1802	high-risk	T033	C0332167
27756035	1803	1805	EC	T191	C0476089
27756035	1806	1814	patients	T101	C0030705